Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro

eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleNew Research, Sensory and Motor Systems

Targeted Activation of Cholinergic Interneurons Accounts for the Modulation of Dopamine by Striatal Nicotinic Receptors

Katherine R. Brimblecombe, Sarah Threlfell, Daniel Dautan, Polina Kosillo, Juan Mena-Segovia and Stephanie J. Cragg
eNeuro 12 October 2018, 5 (5) ENEURO.0397-17.2018; DOI: https://doi.org/10.1523/ENEURO.0397-17.2018
Katherine R. Brimblecombe
1Department of Physiology, Anatomy and Genetics, Sherrington Building, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katherine R. Brimblecombe
Sarah Threlfell
1Department of Physiology, Anatomy and Genetics, Sherrington Building, Oxford, UK
2Oxford Parkinson’s Disease Centre, University of Oxford, Oxford OX1 3PT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah Threlfell
Daniel Dautan
3MRC Anatomical Neuropharmacology Unit, Department of Pharmacology, Oxford, UK
4Center for Molecular and Behavioral Neuroscience, Rutgers University, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Dautan
Polina Kosillo
1Department of Physiology, Anatomy and Genetics, Sherrington Building, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Mena-Segovia
3MRC Anatomical Neuropharmacology Unit, Department of Pharmacology, Oxford, UK
4Center for Molecular and Behavioral Neuroscience, Rutgers University, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Juan Mena-Segovia
Stephanie J. Cragg
1Department of Physiology, Anatomy and Genetics, Sherrington Building, Oxford, UK
2Oxford Parkinson’s Disease Centre, University of Oxford, Oxford OX1 3PT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephanie J. Cragg
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Light activation of rat striatal cholinergic interneurons evokes striatal dopamine release. A, ChR2-eYFP detected in striatum (left) and PPN/LDT (right) after AAV2 injection to PPN/LDT (lower), and detected in striatum only after injection to striatum (upper), fixed tissue. B, GFP-immunopositive soma after striatal injection were co-immunopositive for ChAT. C, E, Mean profiles of [DA]o ± SEM versus time evoked by 1 or 4 pulses (25 Hz) of electrical (C) or light (E) stimulation, in control drug-free conditions or in the presence of DHβE (1 μm). Data are normalized to 1p peak [DA]o in control conditions. Control conditions (black lines), DHβE (red lines). D, F, Mean peak [DA]o normalized to control 1p for electrical (D) and light-evoked DA release (F) in control (black) and in the presence of DHβE (red). n = 3 rats, n = 4 sites. Two-way ANOVA with Sidak posttest comparisons of control versus DHβE: *p < 0.05, ***p < 0.001.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Light activation of striatal cholinergic brainstem afferents with brief stimuli does not reveal dopamine release. A, Left, cartoon indicating PPN/LDT injections sites, and right, recording site labeled with red FluoSpheres in an area of cholinergic brainstem innervation indicated by ChR2-eYFP fluorescence. B, Example profiles of [DA]o (μm) versus time evoked by either light activation of ChIs (ChI ChR2, blue dashed, 1p), electrical stimulation of striatum (black solid line, 1p), or light activation of brainstem cholinergic afferents (brainstem ChR2, blue solid line, 10p 10 Hz). Inset, corresponding voltammograms for DA following each activation type for site indicated in A, at time point indicated on profiles by gray circles. C, Peak evoked [DA]o (μm) for each recording site and stimulation methods, with mean ± SEM indicated. Arrows indicate data points and sites shown in B. D, Mean profiles of current detected at DA oxidation potential (± SEM) versus time evoked by striatal electrical stimulation (1p; black) or light stimulation of ChR2-expressing cholinergic brainstem afferents (10p 10 Hz; blue) in the presence of cocaine (5 μm; n = 10 observations from 3 sites).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Light activation of striatal cholinergic interneurons but not brainstem afferents readily modulates dopamine release. A, C, Mean profiles of [DA]o ± SEM versus time evoked by 1 or 4 pulses (100 Hz) of electrical (E) stimulation alone (left), or with stimulation with light (10p/10 Hz beginning 0.5 s before electrical; right) to stimulate ChR2 expressed in either ChIs (A) or brainstem afferents (C). Data are normalized to 1p control (without light). B, D, Summary data showing mean peak [DA]o ± SEM evoked by the electrical stimulation normalized to control 1p, for ChR2-expressing ChIs (B) or brainstem afferents (D) with and without light activation (blue versus black). Two-way ANOVA with repeated measures with Sidak posttest comparisons of 1p versus 4p: **p < 0.01; N.S., p > 0.05. E, Ratio of [DA]o evoked by 4 versus 1 electrical pulses (100 Hz) with and without light stimulation (blue versus black) of either ChIs or striatal brainstem afferents. Light pre-stimulation of ChIs but not brainstem afferents significantly potentiated 4p:1p ratio of electrically evoked DA release (2-way ANOVA; Sidak posttest for with versus without light: ChI: t18 = 4.1, **p < 0.01; brainstem: t18 = 0.58, p > 0.05). F, Mean peak 1p [DA]o ± SEM, evoked by 0.7 mA and 0.3 mA electrical stimuli, with and without light prestimulation of brainstem afferents. Two-way ANOVA; Sidak posttest with versus without light: 0.7 mA: t12 = 0.29, p > 0.05; 0.3 mA: t12 = 1.2, p > 0.05. Data are in μm, n = 4 rats, n = 6 sites.

Tables

  • Figures
    • View popup
    Table 1.

    Statistical analysis

    LocationData structureType of testPower
    aNormal2-way ANOVA with Sidak posttestInteraction: F1,11 = 8.5, p = 0.014; post hoc test: 1p vs 4p DHβE, p < 0.05
    bNormal2-way ANOVAInteraction: F1,6 = 17.1, p = 0.006; post hoc test: 1p vs 4p, p < 0.05
    cNormal2-way ANOVA (repeated measures)Effect of light: F1,4 = 0.19, p = 0.68; pre-flash × pulse number interaction, F1,4 = 0.02, p = 0.88
    dNormal2-way ANOVAEffect of region: F1,18 = 8.7, p = 0.004; posttest, with vs without prepulse: ChIs, p < 0.01
    eNormal2-way ANOVAEffect of light: F1,12 = 0.2, p = 0.67
Back to top

In this issue

eneuro: 5 (5)
eNeuro
Vol. 5, Issue 5
September/October 2018
  • Table of Contents
  • Index by author
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Targeted Activation of Cholinergic Interneurons Accounts for the Modulation of Dopamine by Striatal Nicotinic Receptors
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Targeted Activation of Cholinergic Interneurons Accounts for the Modulation of Dopamine by Striatal Nicotinic Receptors
Katherine R. Brimblecombe, Sarah Threlfell, Daniel Dautan, Polina Kosillo, Juan Mena-Segovia, Stephanie J. Cragg
eNeuro 12 October 2018, 5 (5) ENEURO.0397-17.2018; DOI: 10.1523/ENEURO.0397-17.2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Targeted Activation of Cholinergic Interneurons Accounts for the Modulation of Dopamine by Striatal Nicotinic Receptors
Katherine R. Brimblecombe, Sarah Threlfell, Daniel Dautan, Polina Kosillo, Juan Mena-Segovia, Stephanie J. Cragg
eNeuro 12 October 2018, 5 (5) ENEURO.0397-17.2018; DOI: 10.1523/ENEURO.0397-17.2018
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • Significance Statement
    • Introduction
    • Methods
    • Results
    • Discussion
    • Footnotes
    • References
    • Synthesis
    • Author Response
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • acetylcholine
  • brainstem
  • cholinergic interneurons
  • dopamine
  • nicotinic receptors
  • striatum

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

New Research

  • Insulin-like growth factor-1 supplementation promotes brain maturation in preterm pigs
  • SK and Kv4 channels limit spike timing perturbations in pacemaking dopamine neurons
  • Evidence for phosphorylation-dependent, dynamic, regulation of mGlu5 and Homer2 in expression of cocaine aversion in mice
Show more New Research

Sensory and Motor Systems

  • Different control strategies drive interlimb differences in performance and adaptation during reaching movements in novel dynamics
  • The nasal solitary chemosensory cell signaling pathway triggers mouse avoidance behavior to inhaled nebulized irritants
  • Taste-odor association learning alters the dynamics of intra-oral odor responses in the posterior piriform cortex of awake rats
Show more Sensory and Motor Systems

Subjects

  • Sensory and Motor Systems

  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2023 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.